Apimeds Pharmaceuticals US APUS
NYSE APUS
$4.48 +0.09 (+2.14%)
As of: Aug 20, 2026 · 3:56 PM EDT

Apimeds Pharmaceuticals US (APUS) Change in Accured Expenses (2024 - 2025)

Apimeds Pharmaceuticals US's (APUS) quarterly Change in Accured Expenses came in at $448494.0 in Q3 2025, up 296.45% YoY from $113128.0 in Q3 2024, and up 154.96% on a QoQ basis from -$816064.0 in Q2 2025.

Apimeds Pharmaceuticals US (APUS) Change in Accured Expenses (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US (APUS) has 2 years of Change in Accured Expenses data on file, last reported at $448494.0 in Q3 2025.

  • Quarterly Change in Accured Expenses rose 296.45% year-over-year to $448494.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $151675.0 (changed N/A YoY) and the FY2024 annual result came in at $536752.0, up 904.48% from the prior year.
  • Change in Accured Expenses grew to $448494.0 in Q3 2025, from -$816064.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $448494.0 in Q3 2025 to a low of -$816064.0 in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Haleon 43.83 Bn 42.86 Bn - -
2 Teva Pharmaceutical Industries 42.87 Bn 39.22 Bn 2.15 Bn 82.00 Mn
3 Zoetis 31.41 Bn 29.73 Bn 1.05 Bn 142.00 Mn
4 Takeda Pharmaceutical 28.55 Bn 22.75 Bn 5.10 Bn -219.00 Mn
5 United Therapeutics 22.08 Bn 19.42 Bn 683.80 Mn -4.00 Mn
6 Viatris 18.73 Bn 17.84 Bn 1.46 Bn -
7 Neurocrine Biosciences 15.44 Bn 15.05 Bn 935.80 Mn -8.50 Mn
8 Elanco Animal Health 11.75 Bn 11.22 Bn 798.00 Mn -
9 Dr Reddys Laboratories 10.11 Bn 9.94 Bn - -
10 Apimeds Pharmaceuticals US 7.68 Mn 7.68 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2025 448,494.00
Sep 30, 2025 448,494.00
Jun 30, 2025 -816,064.00
Jun 30, 2025 -816,064.00
Mar 31, 2025 344,012.00
Mar 31, 2025 344,012.00
Dec 31, 2024 175,233.00
Dec 31, 2024 175,233.00
Sep 30, 2024 113,128.00
Sep 30, 2024 113,128.00
Jun 30, 2024 243,184.00
Jun 30, 2024 243,184.00
Mar 31, 2024 5,207.00
Mar 31, 2024 5,207.00